US2011166343A1PendingUtilityA1

Thienopyrazole derivative having pde7 inhibitory activity

49
Assignee: DAIICHI SANKYO CO LTDPriority: Jul 1, 2004Filed: Mar 14, 2011Published: Jul 7, 2011
Est. expiryJul 1, 2024(expired)· nominal 20-yr term from priority
Inventors:Hidekazu InoueHidenobu MurafujiYasuhiro Hayashi
A61P 37/08A61P 37/06A61P 43/00A61P 9/10A61P 7/00A61P 37/00A61P 9/00A61P 37/02A61P 27/02A61P 29/00A61P 27/16A61P 31/04A61P 25/00A61P 25/28A61P 19/00A61P 17/06A61P 17/00A61P 17/04A61P 1/04A61P 1/16A61P 11/06A61P 1/00A61P 1/18A61P 11/02A61P 11/00A61P 19/02C07D 231/18C07D 495/04A61K 31/4162
49
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

To provide thienopyrazole derivatives inhibiting PDE 7 selectively, and therefore, enhance cellular cAMP level. Consequently, the compound is useful for treating various kinds of disease such as allergic diseases, inflammatory diseases or immunologic diseases. The compound is thienopyrazole compound represented by the following formula (I): [wherein, especially, R 1 is a cyclohexyl, a cycloheptyl group or a tetrahydropyranyl group; R 2 is methyl; R 3 is a hydrogen atom; and R 4 is a group: —CONR 5 R 6 (in which any one of R 5 and R 6 is a hydrogen atom)].

Claims

exact text as granted — not AI-modified
1 - 21 . (canceled) 
     
     
         22 . A compound of the formula (IV): 
       
         
           
           
               
               
           
         
       
       wherein
 R 1  is substituted or unsubstituted C 3 -C 8  alkyl group, substituted or unsubstituted cycloalkyl group or substituted or unsubstituted heterocycloalkyl group; 
 R 2  is a hydrogen atom or C 1 -C 2  alkyl group; 
 and R 3  is a hydrogen atom. 
 
     
     
         23 . (canceled)

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.